Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

4/28/24 8:09:52 PM ET

$PAHC

$ZTS

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PAHC alert in real time by email

Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (NASDAQ:PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024.

This press release features multimedia. View the full release here:

Get the next $PAHC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PAHC
$ZTS

Company	Date	Price Target	Rating	Analyst
Phibro Animal Health Corporation $PAHC	9/10/2024	$22.00	Neutral	JP Morgan
Zoetis Inc. $ZTS	7/25/2024	$220.00	Buy	BTIG Research
Zoetis Inc. $ZTS	1/12/2024	$195.00 → $215.00	Buy	Stifel
Zoetis Inc. $ZTS	12/19/2023	$230.00	Buy	Jefferies
Zoetis Inc. $ZTS	12/7/2023	$237.00	Outperform	Exane BNP Paribas
Phibro Animal Health Corporation $PAHC	12/7/2023	$9.00	Underperform	Exane BNP Paribas
Zoetis Inc. $ZTS	9/6/2023	$230.00	Buy	HSBC Securities
Phibro Animal Health Corporation $PAHC	12/21/2022	$18.00	Buy	ROTH Capital

More analyst ratings

$PAHC
$ZTS
Financials

Live finance-specific insights

Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its first quarter ended September 30, 2024, and its updated financial guidance for the year ending June 30, 2025. Highlights for the three months ended September 30, 2024 (compared to the three months ended September 30, 2023) Net sales of $260.4 million, an increase of $29.1 million, or 13% Net income of $7.0 million, an increase of $15.0 million Diluted income per share of $0.17, an increase of $0.37 Adjusted EBITDA of $30.7 million, an increase of $12.0 million, or 64% Adjusted net income of $14.1 million, an increase of $8.6 million Adjusted diluted EPS of $0.35,
11/6/24 4:35:00 PM ET
$PAHC
Biotechnology: Pharmaceutical Preparations
Health Care
Phibro Animal Health Corporation Declares Quarterly Dividend
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please vi
11/5/24 4:10:00 PM ET
$PAHC
Biotechnology: Pharmaceutical Preparations
Health Care
Zoetis Announces Third Quarter 2024 Results
Reports Revenue of $2.4 Billion, Growing 11%, and Net Income of $682 Million, or $1.50 per Diluted Share, Increasing 14% and 16%, Respectively, on a Reported Basis for Third Quarter 2024 Delivers 14% Operational Growth in Revenue and 15% Operational Growth in Adjusted Net Income for Third Quarter 2024 Reports Adjusted Net Income of $716 Million, or Adjusted Diluted EPS of $1.58, for Third Quarter 2024 Raises Full Year 2024 Revenue Guidance to $9.200 - $9.300 Billion, Representing Operational Revenue Growth of 10% to 11%, with Diluted EPS on an Adjusted Basis of $5.86 to $5.92 Updates Full Year Operational Growth in Adjusted Net Income to 13.5% to 14.5% Zoetis Inc. (NYSE:ZTS)
11/4/24 7:00:00 AM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu
11/11/24 9:20:00 AM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors
Molson Coors' President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors. Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board's Corporate Governance and Sustainability Committee. "Gavin Hattersley brings invaluable experience to our Board as we continue to expand
4/1/24 4:30:00 PM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
Petco Love Announces Newest Board Members
Animal welfare nonprofit bolsters board to better serve the needs of pet lovers nationally SAN ANTONIO, Nov. 14, 2023 /PRNewswire/ -- Petco Love welcomes new members to its board of directors, tapping a wide range of expertise to support its lifesaving mission. Petco Love is committed to shared social values and its diverse and inclusive board composition is a significant reflection of the unified values of its communities served nationwide. Since its founding more than 20 years ago, Petco Love excels as a leader and valued partner in animal welfare by creating a better world
11/14/23 6:03:00 AM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Afte
11/19/24 8:30:00 AM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role
New Commercial Organizational Structure to Accelerate Long-Term Growth Strategy in Key Markets and Optimize Global Commercial Operations Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world's leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company's long-term growth strategy across key markets, drive greater global commercial collaboration and unlock future growth opportunities. This press release features multimedia. View the full release here: https://www.bu
11/11/24 9:20:00 AM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
Zoetis to Participate in Jefferies London Healthcare Conference
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovati
11/7/24 8:30:00 AM ET
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care

Zoetis Announced Earlier It Will Sell Its Medicated Feed Additive Portfolio To Phibro Animal Health For $350M

Chat with this insight

Recent Analyst Ratings for $PAHC$ZTS

$PAHC$ZTS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

$PAHC$ZTS SEC Filings

Phibro Animal Health Corporation filed SEC Form 8-K: Leadership Update

Phibro Animal Health Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Phibro Animal Health Corporation

$PAHC$ZTS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

$PAHC$ZTS Market Insights

Live Market Insights

$PAHC$ZTS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Deep Dive Into Zoetis Stock: Analyst Perspectives (4 Ratings)

BTIG Initiates Coverage On Zoetis with Buy Rating, Announces Price Target of $220

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years

Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

$PAHC$ZTS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JP Morgan initiated coverage on Phibro Animal Health with a new price target

BTIG Research initiated coverage on Zoetis with a new price target

Stifel reiterated coverage on Zoetis with a new price target

$PAHC$ZTS Financials

Live finance-specific insights

Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance

Phibro Animal Health Corporation Declares Quarterly Dividend

Zoetis Announces Third Quarter 2024 Results

$PAHC$ZTS Leadership Updates

Live Leadership Updates

$PAHC$ZTS Press Releases

Fastest customizable press release news feed in the world

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

Petco Love Announces Newest Board Members

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

Zoetis to Participate in Jefferies London Healthcare Conference

$PAHC$ZTS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Sarbaugh Keith claimed ownership of 979 shares (SEC Form 3)

SEC Form 4 filed by Executive Vice President Lagano Roxanne

SEC Form 4 filed by Chief Executive Officer Peck Kristin C

Recent Analyst Ratings for
$PAHC
$ZTS

$PAHC
$ZTS
Insider Purchases

$PAHC
$ZTS
SEC Filings

$PAHC
$ZTS
FDA approvals

$PAHC
$ZTS
Market Insights

$PAHC
$ZTS
Large Ownership Changes

$PAHC
$ZTS
Analyst Ratings

$PAHC
$ZTS
Financials

$PAHC
$ZTS
Leadership Updates

$PAHC
$ZTS
Press Releases

$PAHC
$ZTS
Insider Trading